Antengene to Showcase Novel Cos-TCE Platform Data at SITC 2026…

Event summary

Antengene will present preclinical results of its novel Cos-TCE platform at SITC 2026 on November 6, 2026.
The presentation focuses on a CD2-based costimulatory T cell engager integrating a novel CD3γε/δε-targeting antibody.
Antengene's AnTenGager® platform features proprietary CD3 sequences designed to minimize cytokine release syndrome (CRS).
The company has obtained 35 IND approvals in the U.S. and Asia, with XPOVIO® approved in 10 Asia Pacific markets.

The big picture

Antengene's presentation at SITC 2026 highlights its focus on innovative immunotherapy platforms, particularly in the competitive T cell engager space. The company's strategic partnerships and regulatory progress in Asia Pacific markets position it as a key player in the global biotech landscape. The success of its AnTenGager® platform could further solidify its leadership in developing next-generation cancer therapies.

What we're watching

Clinical Validation: How the preclinical data from the Cos-TCE platform will translate into clinical efficacy and safety.
Partnership Dynamics: Whether Antengene's existing partnerships with UCB and K2 Therapeutics will expand following positive data.
Regulatory Progress: The pace at which Antengene advances its pipeline candidates through regulatory approvals in key markets.